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Abstract
Introduction
The potential impact of targeting different components of an adverse lipid profile in popula-
tions with multiple cardiovascular risk factors is not completely clear. This study aims to
assess the association between different components of the standard lipid profile with all-
cause mortality and hospitalization due to cardiovascular events in a high-risk population.
Methods
This prospective registry included high risk adults over 30 years old free of cardiovascular
disease (2008–2012). Diagnosis of hypertension, dyslipidemia or diabetes mellitus was
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inclusion criterion. Lipid biomarkers were evaluated. Primary endpoints were all-cause mor-
tality and hospital admission due to coronary heart disease or stroke. We estimated
adjusted rate ratios (aRR), absolute risk differences and population attributable risk associ-
ated with adverse lipid profiles.
Results
51,462 subjects were included with a mean age of 62.6 years (47.6% men). During an aver-
age follow-up of 3.2 years, 919 deaths, 1666 hospitalizations for coronary heart disease and
1510 hospitalizations for stroke were recorded. The parameters that showed an increased
rate for total mortality, coronary heart disease and stroke hospitalization were, respectively,
low HDL-Cholesterol: aRR 1.25, 1.29 and 1.23; high Total/HDL-Cholesterol: aRR 1.22, 1.38
and 1.25; and high Triglycerides/HDL-Cholesterol: aRR 1.21, 1.30, 1.09. The parameters
that showed highest population attributable risk (%) were, respectively, low HDL-Choles-
terol: 7.70, 11.42, 8.40; high Total/HDL-Cholesterol: 6.55, 12.47, 8.73; and high Triglycer-
ides/HDL-Cholesterol: 8.94, 15.09, 6.92.
Conclusions
In a population with cardiovascular risk factors, HDL-cholesterol, Total/HDL-cholesterol and
triglycerides/HDL-cholesterol ratios were associated with a higher population attributable
risk for cardiovascular disease compared to other common biomarkers.
Introduction
Between 1990 and 2013, age-standardized death rates from cardiovascular and circulatory dis-
eases fell by 22% in Western Europe, while ischemic heart disease and stroke remain the main
causes of years of life lost [1]. Therefore, primary prevention strategies based on identification
of total cardiovascular risk are essential for cardiovascular disease (CVD) control. Risk assess-
ment tools to estimate the patient’s 10-year risk of developing CVD have become the corner-
stone to identify high-risk people for primary prevention. Both the Framingham-based
equations [2] and the European Systematic COronary Risk Evaluation (SCORE) algorithm [3]
(the most widely used for clinical practice guidelines), include total cholesterol and high den-
sity lipoprotein cholesterol (HDL-C) as the main lipid parameters. The Framingham risk equa-
tions were developed during the peak incidence of CVD in the United States, and they
perform well in similar populations but may overestimate risk by up to 50% in contemporary
European populations, where the incidence of CVD is lower [4]. On the other hand, the
SCORE risk prediction chart assesses risk in people up to 65 years of age, but estimation of
absolute risk of coronary heart disease and CVD in the elderly is needed for targeted preven-
tive activities, particularly in low-incidence, low-mortality Southern European countries,
where life expectancy continues to increase [5].
Low density lipoprotein cholesterol (LDL-C) is the predominant cholesterol-carrying lipo-
protein, and is considered to be the main atherogenic lipoprotein. However other lipoproteins
such as (HDL-C or very low density lipoprotein have shown repeatedly to play a role in athero-
genesis. Recent epidemiological data suggests that isolated low HDL-C in people with normal
LDL-C and triglyceride (TG) levels is equivalent to elevated LDL-C as a coronary risk factor
[6–8]. Moreover, low HDL-C levels and the ratio of total serum cholesterol (TC) to HDL-C
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levels have been introduced in the novel CVD risk scores, such as the QRISK and QRISK2 [9];
the latter being currently recommended by the National Clinical Guideline Centre for Cardio-
vascular Risk Assessment for primary prevention of CVD [10].
There is limited clinical data however, that prospectively evaluates the association of lipid
markers and cardiovascular risk in high-risk populations. In addition, the potential impact on
attributable risk of hypothetical interventions targeting novel lipid markers has not been fully
explored in contemporary populations with additional cardiovascular risk factors such as
hypertension or diabetes. The aim of the present study was to prospectively estimate and com-
pare the attributable risk associated with several lipid markers for all-cause mortality and hos-
pitalization due to CVD in participants with at least one of the three major cardiovascular risk
factors: hypertension, diabetes or dyslipidemia, receiving usual care and participating in the
ESCARVAL-RISK project [11] “EStudio CARdiometabolico VALenciano” in a Mediterranean
population.
Methods
ESCARVAL-RISK is an observational cohort study in individuals with cardiovascular risk fac-
tors (hypertension, dyslipidemia, or diabetes mellitus) and free of previous CVD. Treatment
for hypertension, diabetes or dyslipidemia, as well as other concomitant diseases, was left to
the discretion of primary care physicians and patients were treated according to current clini-
cal guidelines. Therefore, the ESCARVAL-RISK study was specifically designed to investigate
associations between three major cardiovascular risk factors and CVD in the real world setting
of clinical practice.
Study population
The Valencia Community is a Mediterranean region located on the east coast of Spain, with a
total population of 4.980.689 according to the 2015 census. The cohort was recruited from a
sample of patients receiving healthcare by the Valencia Health System. Every user of this sys-
tem has a unique patient identifier, corresponding to a centralized, individual electronic clini-
cal record. The unique patient identifier allows linkage between relevant clinical databases
where various variables were collected. Detailed information about the sample size recruitment
has been published elsewhere [11].
Briefly, we included 73,302 participants of both sexes, aged 30 years or older with a diagno-
sis of hypertension, diabetes mellitus, and/or dyslipidemia, with no previous cardiovascular
events who attended a primary healthcare center for routine health services. Of the total popu-
lation, there was missing data on body weight for 12,209 participants, on serum creatinine for
5,175 participants, and on other variables of interest for 4,456 participants. After excluding
these participants, our final sample size included 51,462 participants. Information was col-
lected from ABUCASIS, which is the electronic health record (EHR) that registers patient data
in the Valencia region.
Baseline data collection
Data on age, sex, smoking and medication for treating hypertension, diabetes, and hypercho-
lesterolemia was collected from the EHR. Blood pressure was measured up to three times on
the same day in the sitting position following the European guidelines on CVD prevention in
clinical practice [12]. Hypertension was defined as a mean systolic blood pressure140 mm
Hg, a mean diastolic blood pressure90 mm Hg, a recorded physician diagnosis, or medica-
tion use. Diabetes was defined as a non-fasting glucose level of200 mg/dl, a recorded physi-
cian diagnosis, medication use, or an HbA1c 6.5%. TC was measured enzymatically using
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the Cholesterol High Performance reagent (Roche Diagnostics). HDL-C was measured using a
direct HDL reagent (Roche Diagnostics). LDL-C was calculated using the Friedwald formula
[13]. High cholesterol was defined as a serum total cholesterol >200 mg/dL, recorded diagno-
sis or medication use. Non-HDL cholesterol was measured according to the difference
between TC and HDL-C. Triglycerides were measured using Hitachi 704 Analyzer which is
serviced by Roche Diagnostics (formerly Boehringer-Mannheim Diagnostics), Indianapolis.
Also non-HDL minus LDL-cholesterol was calculated. Body mass index (BMI) was calculated
by dividing measured weight in kilograms by height in squared meters and obesity was defined
as a BMI30 kg/m2.
Mortality and hospitalization follow-up
The follow up period was from January 2008 to December 2012. Participants were followed up
until the first episode of hospitalization for CHD or stroke or for death. Data on all-cause mor-
tality was collected. At the time of inclusion, information about cardiovascular risk factors and
their active treatments as well as smoking habit and biochemistry lab values were collected
from the EHR. Mortality data were obtained from death certificates registered in the Spanish
National Death Index. The cause of hospitalization was determined by the codes assigned
according to the International Classification of Diseases, 10th Revision (ICD-10). Cause-spe-
cific hospitalization was defined as the first in-hospital admission for CHD (ICD codes 410–
414) or stroke (ICD codes 430–438, 444). Cardiovascular hospitalizations or mortality during
follow-up were assessed by annual mortality and morbidity surveillance reviews of hospitaliza-
tion and death records. Follow-up data was available for 99.8% of subjects for mortality and
for 99.2% of subjects for morbid events. Time to first event was calculated as the difference
between the date of the baseline examination and the date of the hospital admission, date of
death or 31 December 2012, whichever occurred first.
The study was conducted according to the standards of the International Guidelines for
Ethical Review of Epidemiological Studies (Council for International Organizations of Medical
Sciences-CIOMS-Geneva, 1991). The ESCARVAL-RISK study [11] was reviewed and
approved by the Valencia Committee for Ethics and Clinical Trials of the Center for Public
Health Research (DGSP-CSISP). Patient data collected from the ABUCASIS EHR during the
study were anonymized, making it impossible to use the information to identify the patients.
The data generated during the study were handled according the Spanish Law 5/1999 and cor-
responding regulations. All of the researchers with access to study data were required to sign a
document guaranteeing confidentiality. No informed consent from patients was required.
Statistical analysis
Age-adjusted rates for mortality and cardiovascular hospitalization end-points were estimated
using Poisson regression for individual data with over-dispersion correction. Multi-adjusted
rate differences were estimated from semi-parametric Aalen additive hazard models. Statistical
models were adjusted for age (continuous-modelled as restricted cubic splines with five
knots), sex (male, female), BMI (continuous), hypertension (no, yes), hypertension medication
(no, yes), diabetes (no, yes), diabetes medication (no, yes), smoking status (never, former, cur-
rent), high LDL-C (<130 mg/dL,130 mg/dL), low HDL-C (40 mg/dL for men;50 mg/
dL for women) and use of cholesterol-lowering medication (no, yes). Adjusted population
attributable risks (PARs) for dichotomous lipid biomarkers were calculated by using the stan-
dard formula PAR = 1 – SjSi pij / RRi| j [14]. In this formula, the subscript i denotes one of two
categories of the lipid biomarkers (with each participant classified according to the presence of
the corresponding biomarker being used to calculate the PAR), the subscript j is an index for
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all strata obtained after cross-classifying the study sample for all adjusted covariates, pij is the
proportion of total cases in the study population in each stratum after cross-classifying the
dichotomous biomarker category and all adjusted covariates, and RRi|j is the adjusted hazard
ratio for the endpoint of interest comparing participants with and without the biomarker in
stratum j of covariates, from Cox proportional hazards regression. Adjusted PARs represent
the estimated fraction of deaths that would be avoided in the population, had participants
above a given cut-off of the biomarker been below it, assuming that the effects are causal and
that other risk factors remain unchanged. We created 55,000 bootstrap samples to obtain the
standard errors and 95% confidence intervals for PAR.
Results
Participant characteristics
A total of 51,462 patients with at least one cardiovascular risk factor were included in the
study. The main characteristics of the study population, grouped by the study endpoints, are
shown in Table 1. Hypertension was present in 79% and diabetes in 37% of the participants.
Thirty percent were receiving lipid-lowering drug treatment. During an average follow-up of
3.2 years, the EHR recorded 919 deaths (80,705.3 person-years at risk) 1666 hospitalizations
for CHD (78,643.85 person-years at risk) and 1510 stroke hospitalizations (79,130.76 person-
years at risk). Age-adjusted rates (deaths/10,000 person-years) of CVD and mortality end-
points by CVD risk factors per quartiles of each lipid parameter are described in Table 2.
Lipid parameters, mortality and hospitalization for CHD or stroke rates
Age-adjusted mortality rates (deaths/10,000 person-years) showed a significant positive associ-
ation with the TG/HDL-C ratio and an inverse association with TC, HDL-C and LDL-C.
Regarding the risk of hospitalization for CHD, a significant positive association was observed
in non-HDL-C minus LDL-C, TG, TC/HDL-C ratio and TG/HDL-C ratio, and an inverse
relationship with TC, HDL-C and LDL-C. For hospitalization due to stroke, there was a signif-
icant positive association with LDL-C, non-HDL-C minus LDL-C, TG, TC/HDL-C ratio and
TG/HDL-C ratio, and an inverse association with HDL-C. After further adjustment for other
cardiovascular risk factors, however, the association of elevated TC and LDL-C levels and
CHD hospitalization was no longer significant, either in the relative or additive scales (Tables
3 and 4). For stroke, however, the association with LDL-C remained significant in fully
adjusted models. The rate ratio and rate differences (95% CI) for all–cause mortality and CVD
hospitalization after a 3.2-year follow-up comparing the 75th versus 25th percentile of lipid bio-
markers concentrations are shown in the S1 Table, with consistent findings. Fig 1 shows the
fully adjusted dose-response association between lipid values and risk of mortality and hospi-
talization due to CHD and stroke. A sensitivity analysis was performed in participants accord-
ing to current lipid-lowering treatment (S1 Fig), but no relevant differences were found
between groups.
Disease burden associated with lipid parameters
Multi-adjusted differences in rate of events/10,000 person-years of mortality and CVD end-
points (attributable risk) are shown in Table 3. Low HDL-C and a high TC/HDL-C ratio were
associated with the absolute risk of hospitalization for CHD and stroke. High TG/HDL-C also
increased the absolute risk of hospitalization for CHD. The population attributable risks
(PAR) associated with the lipid parameters are shown in Table 4. Low HDL-C, high TC/
HDL-C and high TG/HDL-C were associated with a PAR for mortality of 5.3%, 2.2% and
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5.0%, respectively. For CHD hospitalization the PAR was 8.9%, 7.1% and 9.9%, respectively.
For stroke hospitalization, the attributable risk was low HDL-C (6.6%) and high TC/HDL-C
(4.6%).
Discussion
In this Mediterranean population with at least one major cardiovascular risk factor, HDL-C
levels and the ratios of TC/HDL-C and TG/HDL-C were associated with all-cause mortality
and risk of hospitalization due to CHD and stroke, while LDL-C was associated with stroke
but not with CHD. These data were confirmed in a sensitivity analysis carried out in partici-
pants not receiving lipid-lowering therapy at baseline. The PARs associated with HDL-C, TC/
HDL-C and TG/HDL-C ranged from 4.5% (CI95% 4.4–7.7; PAR of stroke associated to ele-
vated TC/HDL-C) to 9.9% (CI95% 5.8–13.9; PAR of CHD associated with elevated TG/
HDL-C).
Table 1. Participant characteristics according to presence or absence of all-cause mortality and CVD hospitalization end-points.
All-cause mortality CHD hospitalization Stroke hospitalization
Overall
(N = 51,462)
No
(N = 50,543)
Yes
(N = 919)
No
(N = 49,796)
Yes
(N = 1666)
No
(N = 49,952)
Yes
(N = 1510)
Age, mean years (SD) 62.65 (12.07) 62.45 (12.02) 73.37
(10.21)
62.5 (12.1) 67.19 (10.36) 62.41 (12.05) 70.44 (9.89)
Men, % 47.59 47.26 65.61 47.07 63.09 47.35 55.56
BMI, kg/m2, mean (SD) 29.53 (4.83) 29.54 (4.83) 29.19 (4.89) 29.52 (4.84) 29.87 (4.59) 29.54 (4.84) 29.29 (4.55)
Obesity, % 42.09 42.12 40.48 41.99 44.90 42.15 40.07
Former smoking, % 20.78 20.66 27.53 20.39 32.59 20.67 24.57
Current smoking, % 22.22 22.26 20.46 22.39 17.29 22.35 17.95
Diabetes, % 37.20 36.88 54.41 36.62 54.44 36.76 51.59
Glucose lowering medication, % 19.39 19.51 12.95 19.00 31.15 19.14 27.95
Systolic blood pressure, mean
mmHg (SD)
136.24 (18.19) 136.17 (18.16) 140.19
(19.64)
136.11 (18.14) 140.32
(19.26)
136.11 (18.14) 140.75
(19.17)
Diastolic blood pressure, mean
mmHg (SD)
79.36 (10.85) 79.41 (10.84) 76.71
(10.83)
79.4 (10.83) 78.4 (11.37) 79.39 (10.83) 78.52 (11.41)
Hypertension, % 78.98 78.78 90.42 78.55 92.14 78.59 92.05
Antihypertensive medication, % 43.56 43.95 22.20 43.10 57.20 43.27 53.18
Chronic kidney disease, % 15.01 14.69 32.43 14.69 24.31 14.66 26.36
Total cholesterol, mean mg/dL (SD) 211.01 (40.97) 211.26 (40.93) 197.58
(41.02)
211.35 (40.84) 201.02
(43.61)
211.25 (40.9) 203.12
(42.49)
HDL-cholesterol, mean mg/dL (SD) 52.7 (13.94) 52.74 (13.93) 50.55
(13.98)
52.83 (13.94) 48.86 (13.2) 52.76 (13.95) 50.8 (13.38)
Non-HDL-cholesterol, mean mg/dL
(SD)
158.31 (39.41) 158.52 (39.39) 147.04
(38.7)
158.52 (39.3) 152.16 (42) 158.49 (39.36) 152.32
(40.49)
LDL-cholesterol, mean mg/dL (SD) 126.2 (34.33) 126.36 (34.31) 117.62
(34.37)
126.4 (34.25) 120.06
(36.16)
126.34 (34.3) 121.47
(35.03)
Triglycerides, mean mg/dL (SD) 149.69 (100.01) 149.89
(100.29)
138.46
(82.37)
149.47
(100.13)
156.38
(96.15)
149.86
(100.51)
143.95
(81.65)
Ratio total/HDL-cholesterol 4.22 (1.2) 4.22 (1.2) 4.12 (1.17) 4.22 (1.2) 4.34 (1.27) 4.22 (1.2) 4.2 (1.19)
Ratio triglycerides/HDL-cholesterol 3.26 (3.01) 3.26 (3.02) 3.11 (2.69) 3.25 (3.01) 3.63 (3.07) 3.26 (3.03) 3.18 (2.36)
Dyslipidemia, % 88.23 88.39 79.22 88.04 93.76 88.20 89.01
Lipid lowering medication, % 30.28 30.60 12.73 29.80 44.60 30.09 36.76
CVD: cardiovascular disease; CHD: coronary heart disease; SD: statistical deviation; BMI: body mass index; HDL: High density lipoprotein; LDL: low
density lipoprotein
https://doi.org/10.1371/journal.pone.0186196.t001
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Table 2. Age and sex-adjusted rates of all-cause mortality and CVD hospitalization by quartile of serum lipids.
Quartile p-value
Q1 Q2 Q3 Q4
Total cholesterol
Median (range), mg/dL 165 (118, 183) 165 (184, 210) 223 (211, 237) 257 (238, 329)
All-cause mortality
Cases (person-years) 341 (43,630.74) 255 (43,449.59) 184 (41,295.09) 139 (41,238.03)
Rate 60.3 55.5 51.0 49.5 0.027
CHD hospitalization
Cases (person-years) 609 (42,385.83) 429 (42,671.84) 306 (40,716.51) 322 (40,637.52)
Rate 126.0 97.7 80.6 95.2 <0.001
Stroke hospitalization
Cases (person-years) 504 (42,683.04) 388 (42,774.50) 321 (40,668.79) 297 (40,714.40)
Rate 98.3 85.0 84.7 93.9 0.361
HDL cholesterol
Median (range), mg/dL 38 (27, 43) 38 (44, 51) 56 (52, 61) 69 (62, 98)
All-cause mortality
Cases (person-years) 315 (45,630.38) 228 (42,053.36) 191 (42,115.12) 185 (39,814.59)
Rate 66.0 52.9 46.0 50.7 <0.001
CHD hospitalization
Cases (person-years) 633 (44,381.46) 435 (41,240.43) 337 (41,467.21) 261 (39,322.61)
Rate 135.8 103.5 83.7 73.6 <0.001
Stroke hospitalization
Cases (person-years) 487 (44,749.58) 378 (41,346.15) 364 (41,439.38) 281 (39,305.62)
Rate 110.8 90.4 86.3 71.9 <0.001
Non-HDL cholesterol
Median (range), mg/dL 115 (74, 131) 115 (132, 156) 169 (157, 183) 204 (184, 276)
All-cause mortality
Cases (person-years) 325 (43,768.99) 253 (42,218.93) 192 (42,588.25) 149 (41,037.27)
Rate 58.0 55.9 50.0 52.7 0.154
CHD hospitalization
Cases (person-years) 558 (42,614.69) 420 (41,425.83) 352 (41,964.77) 336 (40,406.42)
Rate 117.6 98.0 88.0 96.4 <0.001
Stroke hospitalization
Cases (person-years) 477 (42,867.75) 383 (41,571.73) 339 (41,923.08) 311 (40,478.17)
Rate 92.1 85.2 85.2 99.8 0.492
LDL cholesterol
Median (range), mg/dL 88 (50, 102) 88 (103, 124) 135.75 (125, 148) 166 (149, 224)
All-cause mortality
Cases (person-years) 314 (41,816.10) 246 (41,215.15) 203 (43,304.18) 156 (43,278.03)
Rate 60.9 56.0 50.4 49.7 0.015
CHD hospitalization
Cases (person-years) 577 (40,679.63) 397 (40,445.12) 342 (42,666.73) 350 (42,620.22)
Rate 128.4 95.6 83.1 94.4 <0.001
Stroke hospitalization
Cases (person-years) 460 (40,965.45) 369 (40,527.55) 370 (42,657.15) 311 (42,690.59)
Rate 95.5 85.2 90.2 91.1 0.606
Non-HDL minus LDL cholesterol
Median (range), mg/dL 16.6 (7.6, 21.0) 16.6 (22.0, 30.0) 35 (30.6, 40.3) 48.25 (41.0, 93.0)
(Continued )
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Table 2. (Continued)
Quartile p-value
Q1 Q2 Q3 Q4
All-cause mortality
Cases (person-years) 308 (51,216.52) 239 (42,451.48) 206 (38,554.97) 166 (37,390.47)
Rate 52.6 52.7 53.8 58.5 0.319
CHD hospitalization
Cases (person-years) 449 (50,328.06) 431 (41,582.03) 391 (37,851.46) 395 (36,650.16)
Rate 85.5 99.8 102.5 118.1 <0.001
Stroke hospitalization
Cases (person-years) 448 (50,354.07) 420 (41,656.99) 335 (37,963.04) 307 (36,866.61)
Rate 81.4 94.8 87.7 101.0 0.013
Triglycerides
Median (range), mg/dL 74 (43, 91) 74 (92, 124) 147 (126, 176) 232 (179, 628)
All-cause mortality
Cases (person-years) 256 (43,230.56) 249 (43,280.85) 222 (42,904.17) 192 (40,197.86)
Rate 52.8 53.2 52.0 59.2 0.347
CHD hospitalization
Cases (person-years) 354 (42,575.48) 400 (42,462.60) 426 (42,111.74) 486 (39,261.89)
Rate 80.9 91.6 99.6 130.7 <0.001
Stroke hospitalization
Cases (person-years) 355 (42,606.01) 400 (42,519.69) 410 (42,135.18) 345 (39,579.85)
Rate 77.5 88.2 96.0 101.2 <0.001
Ratio total/HDL cholesterol
Median (range), mg/dL 2.96 (2.11, 3.35) 2.96 (3.38, 4.03) 4.42 (4.06, 4.86) 5.58 (4.92, 8.29)
All-cause mortality
Cases (person-years) 261 (42,536.33) 220 (42,720.99) 238 (42,608.40) 200 (41,747.72)
Rate 53.8 49.1 55.9 58.0 0.276
CHD hospitalization
Cases (person-years) 370 (41,798.70) 392 (41,961.01) 435 (41,806.98) 469 (40,845.02)
Rate 87.2 91.8 102.1 119.8 <0.001
Stroke hospitalization
Cases (person-years) 386 (41,761.15) 366 (42,108.46) 388 (41,901.78) 370 (41,069.34)
Rate 81.3 81.3 92.4 107.3 <0.001
Ratio TG/HDL cholesterol
Median (range), mg/dL 1.20 (0.58, 1.57) 1.20 (1.61, 2.44) 3.05 (2.49, 3.84) 5.49 (3.95, 17.88)
All-cause mortality
Cases (person-years) 229 (42,638.68) 232 (43,056.65) 241 (42,876.82) 217 (41,041.30)
Rate 51.5 49.4 54.6 61.6 0.041
CHD hospitalization
Cases (person-years) 286 (42,105.98) 395 (42,282.16) 466 (42,014.74) 519 (40,008.84)
Rate 70.3 91.1 107.7 133.2 <0.001
Stroke hospitalization
Cases (person-years) 321 (42,083.52) 409 (42,283.75) 398 (42,119.24) 382 (40,354.22)
Rate 73.2 90.2 92.0 107.3 <0.001
CVD: cardiovascular disease; CHD: coronary heart disease; HDL: High density lipoprotein; LDL: low density lipoprotein
Age and sex-adjusted rates: events/10,000 person-years
https://doi.org/10.1371/journal.pone.0186196.t002
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Characteristics of the study population and the source of data
Participants included in the analysis had a sociodemographic profile comparable to the overall
selected population. The age and sex-adjusted rates in our population were lower compared to
the United States and other European countries [4, 5], reflecting a country-specific profile of
low cardiovascular risk, as supported by the SCORE study [3].
Relationship between lipid parameters and cardiovascular risk in
previous studies in Spain
The age-adjusted absolute rates for mortality or hospitalization for CHD or stroke by lipid val-
ues and indexes presented in this paper are consistent with previously published studies car-
ried out in Spain and elsewhere. The relationship between lipid parameters and rates of
cardiovascular risk has been explored previously in Spain, although these were performed in
the 1990s. The ERICE [15] and the FRESCO [5] studies included data from 11 population
cohorts in seven Spanish regions. The results of the FRESCO study were consistent with our
finding that HDL-C was the lipid factor most strongly associated with cardiovascular risk. In
the ERICE study, total cholesterol did not show a statistical association with cardiovascular
Table 3. Rate differences after a 5-year follow-up by altered lipid levels.
All-cause mortality CHD hospitalization Stroke hospitalization
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
High total cholesterol a -10.70 (-18.08,
-3.33)
-16.36 (-24.15,
-8.57)
-30.62 (-41.12,
-20.12)
-5.76 (-16.65,
5.13)
-2.84 (-12.50,
6.82)
11.16 (0.95,
21.38)
Low HDL-cholesterolb 11.55 (4.10,
19.00)
7.79 (0.12, 15.46) 40.46 (30.20,
50.73)
26.55 (16.07,
37.03)
25.61 (15.45,
35.76)
17.96 (7.45,
28.47)
High non-HDL-cholesterolc -18.16 (-37.71,
1.39)
-23.66 (-43.31,
-4.02)
-47.98 (-75.79,
-20.16)
-27.67 (-55.59,
0.25)
-26.68 (-51.56,
-1.80)
-16.05 (-41.12,
9.03)
High LDL-cholesterold -8.32 (-15.04,
-1.60)
-15.26 (-22.30,
-8.22)
-22.51 (-31.72,
-13.29)
-1.88 (-11.32,
7.57)
-3.56 (-12.62,
5.50)
6.91 (-2.46,
16.27)
High non-HDL minus LDL-
cholesterole
5.47 (-1.48,
12.41)
1.53 (-5.57, 8.63) 15.46 (5.53,
25.38)
5.58 (-4.55,
15.71)
3.80 (-5.38,
12.98)
-2.43 (-11.85,
6.99)
High triglyceridesf 0.57 (-6.56, 7.70) -2.02 (-9.69, 5.64) 25.44 (14.97,
35.91)
7.94 (-3.50,
19.37)
10.59 (1.08,
20.09)
-3.61 (-13.74,
6.53)
High total/HDL-cholesterolg 2.17 (-4.97, 9.30) 2.22 (-5.54, 9.99) 18.10 (7.37,
28.83)
23.14 (11.61,
34.67)
16.04 (6.24,
25.84)
14.55 (3.80,
25.31)
High triglycerides/HDL-
cholesterolh
5.14 (-1.93,
12.21)
3.77 (-3.45,
10.98)
35.76 (25.64,
45.87)
22.13 (11.75,
32.51)
12.98 (3.90,
22.06)
4.25 (-5.29,
13.78)
CVD: cardiovascular disease; CI: confidence interval HDL: High density lipoprotein; LDL: low density lipoprotein
Rate Differences: events/10.000 person-years (95%CI)
Model 1 is adjusted for age and sex. Model 2 is Model 1 further adjusted for smoking status (never, former, current), obesity (no, yes), diabetes (no, yes),
hypertension (no, yes), chronic kidney disease (no, yes), anti-hypertensive medication (no, yes), glucose-lowering medication (no, yes), lipid-lowering
medication (no, yes). Models for specific lipid biomarkers have been additionally adjusted as follows
Total-cholesterola is further adjusted by HDL 40 for men and 50 for women (no, yes)
HDL-cholesterolb is further adjusted by LDL 130 mg/dL (no, yes)
Non-HDL-cholesterolc is further adjusted by HDL 40 for men and 50 for women (no, yes)
LDL-cholesterold is further adjusted by HDL 40 for men and 50 for women (no, yes)
Non-HDL minus LDL-cholesterole is further adjusted by HDL 40 for men and 50 for women (no, yes) and LDL-C 130 mg/dL (no, yes)
Triglyceridesf further adjusted by total cholesterol > 200 mg/dL (no, yes) and HDL 40 for men and 50 for women (no, yes)
Total cholesterol/HDLg is further adjusted by total cholesterol (mg/dL); and
Triglycerides/HDLh is further adjusted by total cholesterol (mg/dL).
https://doi.org/10.1371/journal.pone.0186196.t003
ESCARVAL-RISK study
PLOS ONE | https://doi.org/10.1371/journal.pone.0186196 October 18, 2017 9 / 20
events, however it was not sufficiently powered to assess the impact of HDL-C. Recent data
from a study carried out in patients recently diagnosed with diabetes mellitus [16], identified
the ratio of non-HDL-C to HDL-C as a significant predictor of cardiovascular events, while
LDL-C and TC did not show significant associations.
Lipid parameters as predictors of vascular events
Studies performed worldwide in different populations have found associations between car-
diovascular events and low HDL-C [17–26]. Other studies have found associations with the
TC/HDL-C ratio [27–29], yet others have showed conflicting data [30, 31].
Table 4. Population attributable risk (95% CI) for all-cause mortality and CVD hospitalization by altered lipid levels.
Prevalence All-cause mortality CHD hospitalization Stroke hospitalization
High total cholesterola 60.19%
RR 0.83 (0.73, 0.96) 0.95 (0.86, 1.06) 1.14 (1.02, 1.27)
PAR -9.18 (-16.44, -2.12) -2.32 (-7.41, 2.69) 6.60 (1.19, 11.91)
Low HDL-cholesterolb 31.61%
RR 1.19 (1.04, 1.37) 1.31 (1.18, 1.45) 1.23 (1.1, 1.37)
PAR 5.32 (1.02, 9.64) 8.92 (5.41, 12.44) 6.64 (3.09, 10.20)
High non-HDL-cholesterolc 94.51%
RR 0.84 (0.68, 1.05) 0.86 (0.72, 1.02) 0.9 (0.75, 1.09)
PAR -16.71 (-41.12, 5.88) -15.25 (-34.09, 2.50) -9.85 (-29.16, 8.46)
High LDL-cholesterold 43.99%
RR 0.85 (0.74, 0.98) 0.98 (0.88, 1.09) 1.09 (0.98, 1.21)
PAR -5.93 (-11.12, -0.70) -0.76 (-4.54, 3.01) 3.14 (-0.94, 7.20)
High Non-HDL minus LDL-cholesterole 51.14%
RR 1.03 (0.9, 1.17) 1.08 (0.98, 1.19) 0.99 (0.89, 1.1)
PAR 1.08 (-4.68, 6.71) 3.58 (-1.18, 8.28) -0.54 (-5.19, 4.15)
High Triglyceridesf 36.12%
RR 1.05 (0.91, 1.23) 1.11 (0.99, 1.24) 0.99 (0.88, 1.11)
PAR 1.65 (-3.18, 6.33) 3.95 (-0.26, 8.09) -0.49 (-4.63, 3.62)
High Total/HDL-cholesterolg 29.46%
RR 1.1 (0.94, 1.3) 1.31 (1.17, 1.47) 1.2 (1.06, 1.35)
PAR 2.20 (-1.49, 5.88) 7.10 (4.05, 10.17) 4.58 (1.44, 7.70)
High triglycerides/HDL-cholesterolh 39.42%
RR 1.16 (1.01, 1.33) 1.28 (1.16, 1.42) 1.08 (0.97, 1.2)
PAR 4.96 (0.28, 9.61) 9.91 (5.85, 13.91) 2.81 (-1.27, 6.84)
CI: confidence interval; CHD: coronary heart disease; CVD: cardiovascular disease; PAR: population attributable risk; RR: rate ratio; HDL: High density
lipoprotein; LDL: low density lipoprotein
Model 1 is adjusted for age and sex. Model 2 is Model 1 further adjusted for smoking status (never, former, current), obesity (no, yes), diabetes (no, yes),
hypertension (no, yes), chronic kidney disease (no, yes), anti-hypertensive medication (no, yes), glucose lowering medication (no, yes), lipid-lowering
medication (no, yes). Models for specific lipid biomarkers have been additionally adjusted as follows
Total-cholesterola is further adjusted by HDL 40 for men and 50 for women (no, yes)
HDL-cholesterolb is further adjusted by LDL-C 130 mg/dL (no, yes)
Non-HDL-cholesterolc is further adjusted by HDL 40 for men and 50 for women (no, yes)
LDL-cholesterold is further adjusted by HDL 40 for men and 50 for women (no, yes)
Non-HDL minus LDL-cholesterole is further adjusted by HDL 40 for men and 50 for women (no, yes) and LDL-C 130 mg/dL (no, yes)
Triglyceridesf is further adjusted by total cholesterol > 200 mg/dL (no, yes) and HDL 40 for men and 50 for women (no, yes)
Total cholesterol/HDLg is further adjusted by total cholesterol (mg/dL); and
Triglycerides/HDLh is further adjusted by total cholesterol (mg/dL).
https://doi.org/10.1371/journal.pone.0186196.t004
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It seems clear that low HDL-C is a strong and independent risk factor for CVD. HDL-C
particles may act as a protective factor against atherosclerosis via multiple biological mecha-
nisms [32]: effluxing cellular cholesterol, diminishing cellular death, decreasing vascular con-
striction, reducing inflammatory response, protecting from pathological oxidation, combating
bacterial infection, lessening platelet activation, regulating gene expression by virtue of micro-
RNAs, and improving glucose metabolism.
Data from the Jupiter Study [33] has shown that baseline LDL-C was not associated with
CVD events. In another recent publication [34] of data from more than 350,000 people from
three cohorts (REasons for Geographic And Racial Differences in Stroke [REGARDS], Kaiser
Permanente Southern California [KPSC] and Atherosclerosis Risk In Communities [ARIC]) the
results suggested that the association between LDL-C and CHD in contemporary studies may be
diminished by the preferential use of statins in high risk individuals, while the association with
HDL-related markers remains. While we have not found relevant differences between partici-
pants based on treatment at baseline (S1 Fig), we cannot rule out the presence of a time-varying
residual confounding effect by statin use during the follow-up period in our study population.
It is also important to note that with regard to prediction of vascular events, the most com-
monly used predictive scales for cardiovascular risk (Framingham [2], SCORE [3]) consider
total cholesterol, HDL cholesterol and the ratio of total cholesterol to HDL-C to be the strongest
predictors. In the most recent and widely accepted QRISK2 [9], however, the lipid parameter
included for cardiovascular risk calculation is the ratio TC/HDL-C. The NICE dyslipidemia
guideline [10] recommends using the QRISK2 risk assessment tool to assess cardiovascular risk
for the primary prevention of CVD in people aged 84 and younger. So ESCARVAL study results
agree with these data in order to conclude that nowadays, lipid parameters as HDL-C or Total
Cholesterol / HDL-C are more strongly associated with cardiovascular events than the most
used in clinical practice as LDL-C, and are better predictors to estimate the cardiovascular risk,
especially in high risk patients.
Prospective studies measuring not only HDL and LDL cholesterol levels, but also the num-
ber and size of particles, are needed to further elucidate the association between lipid particles
and cardiovascular risk.
Fig 1. Age and sex-adjusted rates ratios for all-cause mortality and CVD hospitalization by serum
lipid levels. Models are adjusted for age, sex, smoking status (never, former, current), obesity (no, yes),
diabetes (no, yes), hypertension (no, yes), chronic kidney disease (no, yes), anti-hypertensive medication (no,
yes), glucose lowering medication (no, yes), lipid-lowering medication (no, yes). Models for specific lipid
biomarkers have been additionally adjusted as follows: 1) Total-cholesterol is further adjusted by HDL 40
for men and 50 for women (no, yes); 2) HDL-cholesterol is further adjusted by LDL.C 130 mg/dL (no,
yes); 3) Non-HDL-cholesterol is further adjusted by HDL 40 for men and 50 for women (no, yes); 4) LDL-
cholesterol is further adjusted by HDL 40 for men and 50 for women (no, yes); 5) Non-HDL minus LDL-
cholesterol is further adjusted by HDL 40 for men and 50 for women (no, yes) and LDL-C 130 mg/dL
(no, yes); 6) Triglycerides is further adjusted by total cholesterol > 200 mg/dL (no, yes) and HDL 40 for men
and 50 for women (no, yes); 7) Total cholesterol/HDL is further adjusted by total cholesterol (mg/dL); and 7)
Triglycerides/HDL is further adjusted by total cholesterol (mg/dL).
https://doi.org/10.1371/journal.pone.0186196.g001
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Multi-adjusted rate differences in mortality or hospitalizations: PAR
In order to further explore the relationship between lipid parameters and cardiovascular risk,
we analyzed the multi-adjusted rate difference in mortality and hospitalizations as well as the
PAR by altered lipid levels (Table 3). This value can be interpreted as the average annual
increase in mortality and risk of hospitalization due to a cardiovascular event on an absolute
scale, attributable to the factor considered and the relative amount of avoidable deaths and
hospitalization in the population studied, respectively.
The PAR provides an estimated measure of the public health impact of a potential interven-
tion targeting specific risk factors, in the hypothetical scenario where the association of these
markers and CVD risk is causal, and the other risk factors remain unchanged. For most of the
evaluated endpoints (mortality and hospitalization for CHD or stroke), low HDL showed a
higher PAR than the other lipid markers included in the study. Few studies have analyzed the
impact of lipid particles and PAR, and their results are inconsistent. The Framingham Off-
spring study followed a cohort with a mean baseline age of 51 years for two decades, finding
that low levels of HDL-C, high LDL-C and high levels of TG in any combination, were associ-
ated with increased CVD risk. In fact, the highest PARs were for the groups including high
LDL-C, especially in the presence of concomitantly low HDL-C and/or high TG [35]. Another
study, in which the incidence was similar to that of the United States in the 1970s, found that
low HDL-C and high TC were associated with a similar PAR to the one found in our study
[36]. Discrepancies on the impact of LDL-C or TC on cardiovascular risk may be explained by
our selection criteria, which included a higher risk profile and higher use of statins. PAR for
cardiovascular risk associated with lipid parameters in other contemporary studies are, how-
ever, scarce.
Strengths and limitations
There are some limitations to the current study that should be mentioned. Firstly, the lower
CVD risk inherent to the Mediterranean population could limit the generalizability of our
results. In addition, the results apply only to individuals with at least one cardiovascular risk
factor and cannot be extrapolated to the general population.
The results of this observational study should be considered within the advantages and limi-
tations of registry-based data [37]: the use of EHRs offers a timely alternative and these data-
bases provide a low-cost means of accessing rich longitudinal data on large populations for
epidemiologic research. Using EHR for data collection reflects real clinical practice, in contrast
to data from clinical trials. Another potential advantage, as in the current study, is the large
number of participants and events, which provided enough statistical power and a valuable
framework in which to assess the attributable risk of mortality, CHD, and stroke to cardiovas-
cular risk factors in the short term in a real life setting.
The mean follow-up was 3.2 years. Although this is a relatively short time period, we evalu-
ated a high risk study population, which resulted in 919 deaths (80,705.3 person-years at risk),
1666 hospitalizations for CHD (78,643.85 person-years at risk), and 1510 hospitalizations for
stroke. Most cardiovascular risk scales predict cardiovascular risk at 10 years, which has been
proposed as a limitation for high-risk populations. It has become increasingly clear that from a
public health perspective and in clinical practice the need for shorter-term scales in order to
intensify interventions, avert clinical inertia and improve therapeutic adherence. The lack of
association between LDL-C and cardiovascular events in the current study could be influenced
by a shorter time scale used, raising the question of whether LDL-C is a good short-term pre-
dictor of cardiovascular events in high-risk patients. In a study with longer follow-up period,
the association between LDL-C and events may be prove to be stronger.
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Conclusions
Clinical trials have clearly established that reduced LDL-C levels are associated with fewer car-
diovascular events in both high- and low-risk populations. However, despite advances in
research for prevention and acute treatment, including new therapeutic agents, cardiovascular
disease is still the first cause of death in developed and developing countries. Identification of
high risk patients is critical in order to propose effective prevention strategies. There is a signif-
icant proportion of patients with LDL-C levels within the normal range, whether in lipid-low-
ering therapy or not, in whom cardiovascular events do not appear to have been satisfactorily
prevented [38]. Many individuals who reach LDL-C targets still possess an atherogenic lipid
profile with residual risk. In a recent meta-analysis, around 15% of people from population
cohorts in Asia had isolated low HDL-C (patients with normal levels of triglycerides and
LDL-C) [39]. We found a similar proportion in our study (Fig 2). In light of these results, one
should consider including low HDL, with normal TG and normal LDL as a higher risk category.
Individuals exhibiting this form of lipid abnormality are at increased risk of CHD, but at the
same time, are not likely to receive lipid-lowering medication according to current clinical
guidelines, based on their levels of triglycerides and LDL-C. So, probably we are not identifying
Fig 2. Proportion of patients with low HDL-cholesterol, including those with isolated low HDL-cholesterol. Comparison between Australian, Asian
and Spanish cohorts. Completed from Huxley RR et al. Circulation. 2011;124:2056–2064) (M = Male; F = Female). Isolated low HDL-cholesterol: patients
with normal levels of triglycerides and LDL-Cholesterol.
https://doi.org/10.1371/journal.pone.0186196.g002
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high risk patients properly. Nowadays, other lipid parameters in addition to LDL-C should
be included for a more accurate evaluation of CV risk and to determine which patients must
receive preventive treatment.
For patients with hypertension, diabetes or dyslipidemia, our results suggest that those with
low HDL or with high ratios of TC/HDL-C or TG/HDL-C belong to a higher risk category for
CVD. According these results, the atherogenic index or HDL-C or TG/HDL-C might be
included in new CVD risk equations in order to increase the validity of the risk patient assess-
ment and to improve the therapeutic decision-making. However, further research using these
risk markers is needed in order to know which one achieves a better risk adjustment model.
In conclusion, this cohort study in a population with high cardiovascular risk shows that
HDL-C and TC/HDL-C and TG/HDL-C ratios may be better predictors for mortality and
CVD than other lipid parameters commonly used in clinical practice, with relevant practical
implications.
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